Business
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update
GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial
About this update from Altimmune, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020 and provided a business update.\n “Throughout 2020 we have put significant effort into developing our pipeline; from advancing our vaccine candidates, AdCOVID and Nasoshield, to IND enabling studies and manufacturing for ALT-801 and HepTcell,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. “Based on our progress, we are poised for a data-rich year, with the expected initiation of NasoShield, ALT-801 and AdCOVID clinical trials.” Recent Highlights Preclinical testing commences on COVID-19 vaccine candidate, AdCOVIDIn collaboration with the University of Alabama at Birmingham (UAB), we have commenced preclinical testing of candidates for our COVID-19 vaccine, AdCOVID. AdCOVID is being developed as a single dose, intranasal vaccine that is designed to activate multiple arms of the immune system including humoral (antibodies), cellular (T-cell) and mucosal immunity.Our platform vaccine technology is ideally suited for pandemic use and based on Phase 2 clinical data obtained with our influenza vaccine candidate, NasoVAX, AdCOVID is expected to meet or exceed key attributes of the World Health Organization’s (WHO) preferred Target Product Profile (TPP) for a COVID-19 vaccine: WHO Preferred Attribute (TPP)1AdCOVID Expected Attribute (based on NasoVAX data) Single doseSeroprotection with single dose administration Rapid onset of protectionStrong serological response at 2 weeks Immunity lasting at least 1 yearSerological response unchanged at 400 days Non-injectedIntranasal administration Temperature stabilityAt least 3 months at 25oC in a liquid formulation Ability to provide at low costHigh yield, scalable manufacturing process 1https://www.who.int/blueprint/priority-diseases/key-action/WHO_Target_Product_Profiles_for_COVID-19_web.pdf It is expected that the studies at UAB will confirm the broad and robust immune response of the vaccine technology and identify the best vaccine candidate for clinical development. The Company is finalizing manufacturing plans, and intends to conduct a Phase 1 clinical trial of AdCOVID in Q4 of this year. NasoShield Phase 1b trial expected to begin in JuneThe Phase 1b clinical trial of Nasosh...